STOCK TITAN

Zeo Scientifix (ZEOX) major holder reports 43.02% aggregate voting control

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Zeo Scientifix, Inc. investor Wendy Grey, through Greyt Ventures, LLC, filed Amendment No. 1 to a Schedule 13D updating her ownership and voting power. She now beneficially owns 1,405,000 shares of common stock, including 1,155,000 shares issuable upon exercise of warrants.

Based on 7,614,941 common shares outstanding as of January 28, 2026, this represents 17.52% of the common stock voting power. Grey also holds 50 shares of Series C Preferred Stock that provide an additional 25.5% of total voting power, giving her aggregate voting power of 43.02%. The added position reflects warrant grants under Zeo Scientifix’s 2021 Equity Incentive Plan in July 2024 and May 2025, and she currently has sole voting and dispositive power over all reported shares while stating no definite plans for major corporate changes.

Positive

  • None.

Negative

  • None.

Insights

Major Zeo Scientifix holder reports 43.02% aggregate voting power.

Wendy Grey, via Greyt Ventures, LLC, reports beneficial ownership of 1,405,000 Zeo Scientifix common shares, including 1,155,000 issuable from warrants. On 7,614,941 common shares outstanding as of January 28, 2026, this equals 17.52% of the common stock voting power.

She also holds 50 shares of Series C Preferred Stock providing an additional 25.5% of total voting power, bringing aggregate voting power to 43.02%. Recent increases stem from warrant grants for 350,000 and 55,000 shares under the 2021 Equity Incentive Plan on July 11, 2024 and May 16, 2025, respectively.

The filing states she has sole voting and dispositive power over these securities and currently has no definite plans for acquisitions, sales, or corporate transactions beyond potential future equity awards. Future company filings may clarify any changes in her ownership or intentions.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The number of shares Beneficially Owned by the Reporting Person consists of 1,405,000 shares of common stock of the Issuer (including 1,155,000 shares of common stock of the Issuer issuable upon exercise of warrants held by the Reporting Person) representing 17.52% of the voting power based on 7,614,941 shares of common stock outstanding as of January 28, 2026, as reported by the Issuer in its 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 29, 2026 and giving effect to the exercise of the warrants held by the Reporting Person. In addition, the Reporting Person holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power. Accordingly, the Reporting Person's aggregate voting power is equal to 43.02%.


SCHEDULE 13D




Comment for Type of Reporting Person:
The number of shares Beneficially Owned by the Reporting Person consists of 1,405,000 shares of common stock of the Issuer (including 1,155,000 shares of common stock of the Issuer issuable upon exercise of warrants held by the Reporting Person) representing 17.52% of the voting power based on 7,614,941 shares of common stock outstanding as of January 28, 2026, as reported by the Issuer in its 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 29, 2026 and giving effect to the exercise of the warrants held by the Reporting Person. In addition, the Reporting Person holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power. Accordingly, the Reporting Person's aggregate voting power is equal to 43.02%.


SCHEDULE 13D


Grey Wendy
Signature:/s/ Wendy Grey
Name/Title:Wendy Grey
Date:02/06/2026
Greyt Ventures, LLC
Signature:/s/ Wendy Grey
Name/Title:Wendy Grey, Manager
Date:02/06/2026
Comments accompanying signature:
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

FAQ

How many Zeo Scientifix (ZEOX) shares does Wendy Grey beneficially own?

Wendy Grey beneficially owns 1,405,000 Zeo Scientifix common shares, including 1,155,000 issuable upon warrant exercise. This total is calculated against 7,614,941 common shares outstanding as of January 28, 2026, as disclosed in the company’s 2025 Annual Report.

What percentage of Zeo Scientifix (ZEOX) common stock voting power does Wendy Grey hold?

Wendy Grey’s 1,405,000 common shares represent 17.52% of Zeo Scientifix’s common stock voting power. This percentage is based on 7,614,941 shares outstanding as of January 28, 2026, and includes shares issuable upon exercise of her warrants.

How does Wendy Grey reach 43.02% total voting power in Zeo Scientifix (ZEOX)?

Wendy Grey holds 17.52% voting power through common stock and warrants plus 50 Series C Preferred shares that provide an additional 25.5% of total voting power. Combined, these positions give her aggregate voting power of 43.02% in Zeo Scientifix.

What new securities did Wendy Grey receive from Zeo Scientifix (ZEOX) under the 2021 plan?

She received warrants for 350,000 common shares on July 11, 2024, and warrants for 55,000 common shares on May 16, 2025. Both grants were issued under Zeo Scientifix’s 2021 Equity Incentive Plan at a stated price of $0.00 per warrant grant.

Does Wendy Grey have plans to change control or strategy at Zeo Scientifix (ZEOX)?

The filing states Wendy Grey has no current plans or proposals for mergers, major asset sales, board changes, or other significant corporate actions. She notes only that future open-market or plan-related transactions may occur in compliance with applicable securities laws.

What powers does Wendy Grey have over her Zeo Scientifix (ZEOX) holdings?

The filing reports that Wendy Grey has sole voting and sole dispositive power over all 1,405,000 common shares she beneficially owns. This means she alone can decide how these shares are voted and whether, when, and how they are sold or transferred.
ZEO ScientifiX

OTC:ZEOX

ZEOX Rankings

ZEOX Latest News

ZEOX Latest SEC Filings

ZEOX Stock Data

9.87M
3.21M
45.68%
Biotechnology
Healthcare
Link
United States
Davie